Inhaled nitric oxide reverses cell-free hemoglobin-induced pulmonary hypertension and decreased lung compliance. Preliminary results

Table 1 Hemodynamic data (mean ± SEM)

Variable	Baseline	ααHb	NO 5 ppm	OFF	NO 10 ppm	OFF
MAP (mmHg)	97 ± 3.9	119 ± 7.0	117 ± 9.7	120 ± 10.4	117 ± 7.7	116 ± 10.2
CVP (mmHg)	4.0 ± 1.5	6.5 ± 1.3	4.8 ± 1.4	4.9 ± 0.9	4.5 ± 1.9	4.8 ± 1.7
PAOP (mmHg)	9.6 ± 1.9	12.6 ± 1.7	11.2 ± 1.9	10.6 ± 1.5	10.4 ± 1.3	12.4 ± 2.5
HR (beats/min)	106 ± 3.9	88 ± 4.5	90 ± 7.6	92 ± 6.7	91 ± 5.6	95 ± 5.8
Cl (ml/min/m²)	4.7 ± 0.4	4.2 ± 0.1	3.5 ± 0.4	3.4 ± 0.5	3.7 ± 0.5	3.2 ± 0.5
SVRI (dyn s/cm⁵m²)	1603 ± 100	2152 ± 147	2952 ± 492	2952 ± 570	2655 ± 348	3286 ± 559
PVRI(dyn s/cm⁵m²)	291 ± 67	513 ± 92	485 ± 114	657 ± 139	396 ± 73	663 ± 146
SvO₂(%)	93 ± 0.1	80 ± 4.3	78 ± 8.4	78 ± 7.8	77 ± 5.7	77 ± 7.9

ααHb: αα-crosslinked hemoglobin 200 mg/kg; NO 5ppm = 5ppm inhaled nitric oxide; NO 10 ppm = 10 ppm inhaled nitric oxide; OFF = nitric oxide discontinued; MAP = mean arterial pressure; CVP = central venous pressure; PAOP = pulmonary artery occlusion pressure; HR = heart rate; CI = cardiac index; SVRI = systemic vascular resistance index; PVRI = pulmonary vasclar resistance index; SvO₂ = mixed venous oxygen saturation ^*P<0.05 compared to baseline.

ISSN: 1364-8535